Healthcare
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" in October 2025, Marking the Company's Transition to the U.S. Public Markets KUALA LUMPUR, Malaysia, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, toda
About this update from Alps Group Inc
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" in October 2025, Marking the Company's Transition to the U.S. Public Markets KUALA LUMPUR, Malaysia, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update. The Company has filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (the "SEC") on August 6, 2026. Alps' Form 20-F can be accessed on the "Investors Relations" section of its website at https://investor.alps-holdings.com/, as well as on the SEC's website at www.sec.gov. Shareholders may also request a hard copy of the Form 20-F annual report that includes audited financial statements, free of charge, by sending an e-mail to Alps' IR firm at [email protected]. "Fiscal year 2026 was a transformational year for Alps. We completed our Business Combination with Globalink Investment Inc. and began trading on the Nasdaq Global Market under the ticker symbol 'ALPS,' giving us a stronger platform to execute against our long-term strategy," said Dr. Tham Seng Kong, Managing Director and Group Chief Executive Officer of Alps Group Inc. "At the same time, we grew revenue 44% year-over-year, advanced our cellular therapy pipeline and sharpened our research and development focus on the areas where we see the greatest opportunity to deliver value for patients and shareholders." Fiscal Year 2026 Business Highlights Recent Developments Fiscal Year 2026 Financial Results About Alps Group Inc Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia. Forward-Looking Statements Certain statements in this press release may be considered to contain certain "forward-looking statements" within the meaning of "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. A further list and description of risks and uncertainties can be found in the Company's Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the SEC on August 6, 2026, and in other documents that the Company may file or furnish with the SEC, which you are encouraged to read. This press release should be read in conjunction with the audited consolidated and combined financial statements and related notes included in that Annual Report on Form 20-F. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law. Investor Relations Contact Philip Carlson KCSA Strategic Communications Phone: 212.896.1233 Email: [email protected] Comparison of Results of Operations for the Fiscal Years Ended March 31, 2026, 2025 and 2024 Basis of Presentation The financial information in this press release is presented in U.S. dollars and has been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The Business Combination completed in October 2025 was accounted for as a capital reorganization. Percentages and dollar amount in the narrative above are rounded. The following table summarizes the consolidated and combined results of operations for the fiscal years ended March 31, 2026, 2025 and 2024: Cash Flows for the Fiscal Year Ended March 31, 2026, 2025 and 2024 The following table sets forth a summary of our cash flow for the year ended March 31, 2026, 2025 and 2024: